Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) shares reached a new 52-week low during trading on Monday . The company traded as low as $7.97 and last traded at $8.09, with a volume of 400639 shares trading hands. The stock had previously closed at $8.43.
Analyst Upgrades and Downgrades
Several research analysts have weighed in on the company. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Wells Fargo & Company cut their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, February 20th. StockNews.com cut Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, February 20th. Morgan Stanley reaffirmed an "equal weight" rating and issued a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, Amicus Therapeutics has an average rating of "Moderate Buy" and an average price target of $16.75.
Read Our Latest Stock Report on FOLD
Amicus Therapeutics Stock Performance
The firm has a market cap of $2.30 billion, a P/E ratio of -41.67, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69. The stock's 50-day moving average price is $9.16 and its 200 day moving average price is $9.88. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42.
Institutional Investors Weigh In On Amicus Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in FOLD. Virtus Fund Advisers LLC acquired a new position in Amicus Therapeutics during the fourth quarter worth $29,000. Covestor Ltd increased its stake in shares of Amicus Therapeutics by 114.9% during the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock worth $41,000 after purchasing an additional 2,312 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Amicus Therapeutics in the 3rd quarter valued at about $55,000. GF Fund Management CO. LTD. acquired a new stake in Amicus Therapeutics in the 4th quarter valued at about $59,000. Finally, R Squared Ltd bought a new position in Amicus Therapeutics during the fourth quarter worth about $79,000.
Amicus Therapeutics Company Profile
(
Get Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Featured Stories
Before you consider Amicus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.
While Amicus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
